tceb-3 Antibody

What methods are most effective for detecting TCEB3 expression in tissue samples?

For reliable detection of TCEB3 expression in tissue samples, immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR) are the most widely used and effective methods . Studies have successfully employed these techniques to compare TCEB3 levels between cancerous tissues and adjacent normal tissues. When conducting IHC analysis, it is recommended to use paraffin-embedded sections (4-6 μm thickness) with appropriate antigen retrieval methods. For qRT-PCR, extraction of high-quality RNA followed by reverse transcription and amplification with TCEB3-specific primers yields quantitative measurements of expression levels . Western blotting provides an additional method for protein-level detection, particularly useful when evaluating the effects of experimental manipulations on TCEB3 expression.

How should researchers design experiments to study TCEB3 function in cell lines?

When designing experiments to study TCEB3 function in cell lines, researchers should consider a multi-faceted approach that includes:

• Expression analysis: Initial characterization of endogenous TCEB3 levels across multiple cell lines using qRT-PCR and Western blot to select appropriate experimental models .

• Loss-of-function studies: Implementation of siRNA or shRNA targeting TCEB3, with verification of knockdown efficiency (>70% reduction is typically desired) .

• Functional assays: Assessment of cellular phenotypes including:

  • Proliferation (CCK-8 or MTT assays)

  • Colony formation capability

  • Invasion/migration (transwell assays)

  • Apoptosis (flow cytometry with Annexin V/PI staining)

• Molecular marker analysis: Evaluation of relevant downstream effectors such as Ki-67 (proliferation), MMP-2 and MMP-9 (invasion) via Western blot .

For optimal results, researchers should include appropriate controls and perform experiments in multiple cell lines to ensure reproducibility and broader relevance of findings.

What is the relationship between TCEB3 and miRNA regulation in cancer progression?

TCEB3 has been identified as a direct target of miR-140-3p in cancer cells, establishing an important regulatory axis in cancer progression . Research has demonstrated that miR-140-3p expression is generally downregulated in various cancers, including cervical cancer, while TCEB3 expression is upregulated . This inverse relationship suggests miR-140-3p functions as a tumor suppressor by negatively regulating TCEB3.

The mechanistic relationship has been confirmed through multiple approaches:

• Bioinformatics analysis identified TCEB3 as a potential target of miR-140-3p

• Dual-luciferase reporter assays demonstrated direct interaction between miR-140-3p and the 3'-UTR of TCEB3

• Functional studies showed that miR-140-3p inhibition increased TCEB3 expression and promoted cancer cell proliferation and invasion

This regulatory relationship extends further to include circular RNA (circRNA) interactions, with circ-0000212 functioning as a molecular sponge for miR-140-3p, thereby indirectly upregulating TCEB3 expression . This circ-0000212/miR-140-3p/TCEB3 axis represents an important regulatory pathway in cancer progression that could be targeted for therapeutic interventions.

How can researchers optimize antibody-based detection systems for TCEB3?

Optimizing antibody-based detection systems for TCEB3 requires careful consideration of several technical factors:

• Antibody selection: Choose antibodies validated for the specific application (WB, IHC, IF) and species of interest. Monoclonal antibodies typically offer higher specificity while polyclonal antibodies may provide stronger signals.

• Protocol optimization:

  • For Western blot: Determine optimal protein loading (typically 20-40 μg), transfer conditions, antibody dilution (typically 1:500-1:2000), and incubation time (overnight at 4°C often yields best results) .

  • For IHC: Optimize antigen retrieval methods (heat-induced epitope retrieval in citrate buffer pH 6.0 or EDTA buffer pH 9.0), blocking (5% BSA or serum), antibody dilution (typically 1:100-1:500), and detection system.

• Validation strategies:

  • Include positive and negative control tissues/cells with known TCEB3 expression levels

  • Perform antibody validation using TCEB3 knockout or knockdown samples

  • Consider dual-detection methods (e.g., confirming IHC results with Western blot or qRT-PCR)

• Signal amplification: For low-abundance targets, implement signal amplification methods such as tyramide signal amplification (TSA) or polymer-based detection systems.

By systematically optimizing these parameters, researchers can achieve reliable and reproducible detection of TCEB3 across various experimental contexts.

What are the most informative experimental models for studying TCEB3 function in cancer?

The selection of appropriate experimental models is crucial for studying TCEB3 function in cancer. Based on current research, the following models have proven most informative:

• Cell line models:

  • Human cervical cancer cell lines (SiHa, HT-3, HeLa, C33A) exhibit varying levels of TCEB3 expression and provide versatile in vitro systems

  • Normal human keratinocytes (HaCaT) serve as appropriate controls for comparison

• Patient-derived samples:

  • Paired tumor and adjacent normal tissues from cervical cancer patients provide clinically relevant contexts for expression analysis

  • Tissue microarrays allow for high-throughput screening across multiple patient samples

• Genetic manipulation models:

  • TCEB3 knockdown using siRNA or shRNA systems allows for assessment of loss-of-function effects

  • CRISPR/Cas9-mediated knockout can establish stable cell lines for long-term studies

  • Overexpression models using expression vectors can evaluate gain-of-function effects

• Animal models:

  • Xenograft models using TCEB3-manipulated cancer cells can assess in vivo tumor growth and metastasis

  • Genetically engineered mouse models could provide insights into tissue-specific effects of TCEB3 alteration

What are the critical controls needed when using TCEB3 antibodies for Western blot analysis?

When performing Western blot analysis with TCEB3 antibodies, implementing comprehensive controls is essential for result validation and troubleshooting:

• Sample-level controls:

  • Positive control: Cell lines or tissues with confirmed high TCEB3 expression (e.g., SiHa or HeLa cells for cervical cancer studies)

  • Negative control: Cells with minimal TCEB3 expression or TCEB3 knockdown/knockout samples

  • Loading control: Detection of housekeeping proteins (β-actin, GAPDH, or α-tubulin) to normalize expression levels

• Antibody controls:

  • Primary antibody omission: To assess non-specific binding of secondary antibody

  • Isotype control: Incubation with non-specific IgG of the same species as the primary antibody

  • Peptide competition: Pre-incubation of antibody with blocking peptide to confirm specificity

• Expression manipulation controls:

  • siRNA/shRNA knockdown: Demonstrates antibody specificity through reduced signal intensity

  • Overexpression: Confirms antibody detection capability through increased signal

• Technical controls:

  • Molecular weight markers: To confirm the detection of protein at the expected size (TCEB3: approximately 110 kDa)

  • Gradient of protein loading: To verify linear dynamic range of detection

Implementing these controls systematically allows researchers to validate antibody specificity, optimize detection conditions, and confidently interpret Western blot results for TCEB3 expression analysis.

How can researchers effectively silence TCEB3 expression for functional studies?

Effective silencing of TCEB3 expression is critical for conducting meaningful functional studies. Based on successful approaches in the literature, researchers should consider the following methodological guidelines:

• siRNA transfection approach:

  • Design or obtain multiple siRNA sequences targeting different regions of TCEB3 mRNA

  • Test knockdown efficiency of each siRNA (typically 2-3 different sequences) to identify the most effective option

  • Optimize transfection conditions: cell density (typically 60-70% confluence), transfection reagent (Lipofectamine™ or similar), siRNA concentration (typically 20-50 nM), and duration (48-72 hours)

  • Include appropriate controls: non-targeting siRNA (negative control) and positive control siRNA targeting a housekeeping gene

• shRNA approach for stable knockdown:

  • Design shRNA sequences based on effective siRNA sequences

  • Establish stable cell lines through lentiviral or retroviral transduction

  • Select transduced cells using appropriate antibiotic resistance

  • Validate knockdown efficiency through qRT-PCR and Western blot analysis

• CRISPR/Cas9 for gene knockout:

  • Design guide RNAs targeting early exons of TCEB3

  • Screen and isolate single-cell clones

  • Verify knockout through sequencing and Western blot analysis

• Validation of functional outcomes:

  • Confirm knockdown at both mRNA (qRT-PCR) and protein (Western blot) levels

  • Assess phenotypic changes using assays for proliferation, colony formation, invasion, and apoptosis

  • Examine expression of downstream markers (Ki-67, MMP-2, MMP-9) to confirm functional consequences

The choice between transient (siRNA) and stable (shRNA or CRISPR) approaches depends on the experimental timeline and specific research questions. For initial characterization, siRNA approaches offer flexibility and rapid results, while stable systems are preferable for long-term studies and in vivo experiments.

What methodologies are most effective for studying the interaction between TCEB3 and its regulatory miRNAs?

Investigating the interaction between TCEB3 and its regulatory miRNAs, particularly miR-140-3p, requires specialized methodologies that can confirm direct binding and functional consequences. The following approaches have proven effective:

• Prediction and identification of interactions:

  • Bioinformatic analysis using databases such as miRDB, TargetScan, or miRanda to predict miRNA binding sites in TCEB3 3'UTR

  • Expression correlation analysis between TCEB3 and candidate miRNAs in tissue samples and cell lines

• Validation of direct interaction:

  • Dual-luciferase reporter assay: Construct reporters containing wild-type and mutated TCEB3 3'UTR binding sites to confirm direct miRNA targeting

  • Site-directed mutagenesis of predicted binding sites to identify critical interaction regions

  • RNA immunoprecipitation (RIP) assay to confirm the association of TCEB3 mRNA with miRNA-induced silencing complex (miRISC) components

• Functional characterization:

  • Transfection of miRNA mimics or inhibitors to modulate miRNA levels (e.g., miR-140-3p inhibitor)

  • Rescue experiments combining miRNA modulation with TCEB3 overexpression or knockdown

  • Assessment of downstream effects on cellular phenotypes (proliferation, invasion, apoptosis)

• Analysis of competing endogenous RNA (ceRNA) mechanisms:

  • Identification of circular RNAs (e.g., circ-0000212) that may sponge regulatory miRNAs

  • RNA pull-down assays to confirm physical interactions between circRNAs and miRNAs

  • Co-transfection experiments to validate the ceRNA regulatory model

These comprehensive approaches allow researchers to establish and characterize the regulatory relationship between TCEB3 and its miRNA regulators, providing insights into potential therapeutic targeting of this axis in cancer.

What are the key considerations for developing novel antibodies against TCEB3?

Developing novel antibodies against TCEB3 requires careful attention to several critical factors to ensure specificity, sensitivity, and functional utility:

• Epitope selection strategy:

  • Target unique regions of TCEB3 with high antigenicity and low homology to related proteins

  • Consider epitopes representing functional domains or regulatory regions

  • Balance hydrophilicity, accessibility, and conservation across species if cross-reactivity is desired

• Production approach options:

  • Monoclonal antibodies: Provide high specificity but target single epitopes

  • Polyclonal antibodies: Recognize multiple epitopes but may have higher background

  • Recombinant antibodies: Offer consistent production and engineering possibilities

• Validation requirements:

  • Confirm specificity using TCEB3 knockout/knockdown samples

  • Test cross-reactivity with related proteins

  • Validate across multiple applications (WB, IHC, IP, IF) if multipurpose use is intended

  • Assess performance in relevant tissue types and experimental conditions

• Advanced antibody engineering:

  • Consider sequence-based design approaches similar to those used in DyAb methodology, which has successfully generated antibodies with improved binding properties

  • Implement prediction algorithms to optimize antibody properties, as demonstrated in recent antibody design studies

  • Use genetic algorithms to improve binding affinity, as shown for other antibody targets

For researchers developing new TCEB3 antibodies, implementing a rigorous validation pipeline is essential to ensure that the antibodies perform reliably across intended applications and experimental systems.

How can researchers optimize TCEB3 antibodies for improved binding affinity and specificity?

Optimization of TCEB3 antibodies for enhanced binding affinity and specificity can be approached through several methodological strategies:

• Sequence-based optimization:

  • Apply computational approaches like those used in DyAb methodology to predict beneficial mutations

  • Implement genetic algorithms to explore sequence space and iteratively improve binding properties

  • Combine beneficial point mutations identified in individual variants to create optimized antibodies

• Experimental screening approaches:

  • Develop display libraries (phage, yeast, or mammalian) of antibody variants

  • Perform affinity maturation through iterative rounds of selection

  • Test binding kinetics using surface plasmon resonance (SPR) or bio-layer interferometry (BLI)

• Structure-guided engineering:

  • If structural data is available, target mutations to the complementarity-determining regions (CDRs)

  • Focus on binding interface residues that directly contact the epitope

  • Consider computational approaches for predicting stabilizing mutations

• Performance evaluation metrics:

  • Measure improvements in binding affinity (KD) through titration experiments

  • Assess specificity through cross-reactivity testing with related proteins

  • Evaluate expression levels and stability of optimized variants

  • Confirm maintained or improved performance in intended applications

Recent antibody optimization studies have demonstrated that combining complementary mutations can yield substantial improvements in binding affinity, with examples showing up to 50-fold enhancement compared to parent antibodies . Similar approaches could be applied to TCEB3 antibodies to develop variants with superior research and potential therapeutic properties.

What are the most promising applications of TCEB3 antibodies in cancer therapy research?

TCEB3 antibodies hold significant potential for various applications in cancer therapy research, based on the established role of TCEB3 in promoting cancer progression through the circ-0000212/miR-140-3p/TCEB3 axis :

• Targeted therapy development:

  • Use of antibodies to block TCEB3 function directly in cancer cells

  • Development of antibody-drug conjugates (ADCs) targeting TCEB3-expressing cells

  • Creation of bispecific antibodies linking TCEB3 recognition with immune effector recruitment

• Diagnostic and prognostic applications:

  • Development of immunoassays for TCEB3 detection in patient samples

  • Creation of companion diagnostics to identify patients likely to respond to TCEB3-targeted therapies

  • Monitoring of treatment response through TCEB3 expression analysis

• Mechanistic research applications:

  • Interrogation of TCEB3 protein-protein interactions using co-immunoprecipitation

  • Investigation of TCEB3's role in transcriptional elongation complexes

  • Exploration of TCEB3's contribution to the ubiquitylation and degradation of Rpb1

• Therapeutic screening platforms:

  • Development of high-throughput screening assays using TCEB3 antibodies to identify small molecule inhibitors

  • Creation of reporter systems to monitor TCEB3 expression in response to potential therapeutics

The promising role of TCEB3 as a novel therapeutic target is supported by patient survival data showing that high TCEB3 expression correlates with lower survival rates in cervical cancer patients . This finding, combined with the demonstrated effects of TCEB3 silencing on cancer cell phenotypes, underscores the potential value of TCEB3 antibodies in cancer therapy research.

What statistical approaches are most appropriate for analyzing TCEB3 expression data?

• Comparison between two groups (e.g., tumor vs. normal):

  • For normally distributed data: Student's t-test

  • For non-normally distributed data: Mann-Whitney U test

  • Paired samples (e.g., matched tumor-normal): Paired t-test or Wilcoxon signed-rank test

• Comparison across multiple groups:

  • One-way ANOVA followed by post-hoc tests (e.g., Tukey's, Bonferroni) for normally distributed data

  • Kruskal-Wallis followed by Dunn's test for non-normally distributed data

• Correlation analysis:

  • Pearson correlation coefficient for linear relationships between normally distributed variables

  • Spearman rank correlation for non-parametric relationships

  • Particularly useful for examining relationships between TCEB3 and miR-140-3p expression

• Survival analysis:

  • Kaplan-Meier method with log-rank test to compare survival between high and low TCEB3 expression groups

  • Cox proportional hazards regression for multivariate analysis incorporating clinical variables

• Experimental design considerations:

  • Power analysis to determine appropriate sample sizes

  • Control for multiple testing when examining numerous variables (e.g., Bonferroni correction, false discovery rate)

  • Include biological replicates (minimum n=3) for all experiments

In published TCEB3 research, statistical significance is typically set at P<0.05 or P<0.01, with data presented as mean ± standard deviation (SD) or standard error of the mean (SEM) . Researchers should clearly report all statistical methods, sample sizes, and significance levels when publishing TCEB3 expression analysis results.

How should researchers design experiments to investigate the therapeutic potential of targeting TCEB3?

Designing rigorous experiments to investigate the therapeutic potential of targeting TCEB3 requires a comprehensive approach spanning in vitro, in vivo, and translational studies:

• In vitro therapeutic assessment:

  • Compare multiple targeting strategies: siRNA/shRNA knockdown , CRISPR knockout, antibody-based inhibition, small molecule inhibitors

  • Evaluate effects on cancer cell phenotypes: proliferation, invasion, apoptosis, and colony formation

  • Assess impact on molecular markers of proliferation (Ki-67) and invasion (MMP-2, MMP-9)

  • Test in multiple cell lines to ensure broad applicability of findings

• In vivo model development:

  • Xenograft models using TCEB3-manipulated cancer cells

  • Patient-derived xenografts to better reflect tumor heterogeneity

  • Genetically engineered mouse models if available

  • Include appropriate controls: scrambled shRNA, non-targeting CRISPR, isotype control antibodies

• Combination therapy approaches:

  • Test TCEB3 targeting in combination with standard chemotherapeutics

  • Explore synergies with other targeted therapies (e.g., miR-140-3p mimics)

  • Investigate potential for enhancing immunotherapy responses

• Translational research components:

  • Develop biomarker strategies to identify patients likely to respond to TCEB3-targeted therapies

  • Establish patient-derived organoid models for personalized therapy testing

  • Correlate TCEB3 expression levels with response to existing therapies in retrospective patient cohorts

• Mechanistic studies:

  • Investigate effects on the circ-0000212/miR-140-3p/TCEB3 regulatory axis

  • Examine impacts on downstream signaling pathways

  • Identify potential resistance mechanisms

Each experimental approach should include appropriate controls, sufficient biological replicates, and rigorous statistical analysis to ensure the reliability and reproducibility of findings regarding TCEB3's therapeutic potential.

What are the typical experimental protocols for analyzing TCEB3-protein interactions?

Analyzing TCEB3-protein interactions requires specialized protocols that can capture both stable and transient interactions within the cellular context. The following methodological approaches are recommended:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells in non-denaturing buffer to preserve protein complexes

  • Immunoprecipitate with anti-TCEB3 antibody or antibody against the interacting protein partner

  • Include appropriate controls: IgG control, input lysate, and reverse Co-IP

  • Analyze by Western blot using antibodies against suspected interaction partners

  • For detecting components of the elongin complex, special attention to buffer conditions may be necessary

• Proximity ligation assay (PLA):

  • Fix cells and perform permeabilization

  • Incubate with primary antibodies against TCEB3 and potential interacting partners

  • Apply species-specific PLA probes with complementary oligonucleotides

  • Perform ligation and amplification steps

  • Visualize interaction signals using fluorescence microscopy

  • Quantify signals to assess interaction strength

• Bimolecular fluorescence complementation (BiFC):

  • Create fusion constructs of TCEB3 and potential partners with complementary fragments of fluorescent proteins

  • Co-transfect constructs into appropriate cell lines

  • Assess reconstitution of fluorescence signal indicating protein proximity

  • Include appropriate controls: non-interacting protein pairs, single constructs

• Mass spectrometry-based approaches:

  • Immunoprecipitate TCEB3 complexes

  • Perform tryptic digestion

  • Analyze by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

  • Use label-free quantification or SILAC approaches for comparative studies

  • Validate novel interactions using orthogonal methods (Co-IP, PLA)

These protocols enable comprehensive analysis of TCEB3's interactions with components of the elongin complex, ubiquitylation machinery, and potentially novel protein partners involved in cancer progression pathways.